CurrentUnitedHealthcarePolicy 2026T0105EE

Discogenic Pain Treatment

This policy governs coverage and medical necessity determination for procedures intended to treat discogenic low back pain for UnitedHealthcare Commercial and Individual Exchange members, including annular closure devices, thermal intradiscal procedures, and percutaneous allogeneic cellular/tissue-based injections.

Policy Summary

PayerUnitedHealthcare

PolicyDiscogenic Pain Treatment

Policy CodePolicy 2026T0105EE

Change TypeTemplate updateno material clinical changes

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain prior authorization and provide documentation of failed conservative therapy and procedure-specific evidence (e.g., annular defect size for ACD or trial enrollment/justification for allogeneic injections) when requesting coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3procedures unproven / not medically necessary

0627T–0630Texample codes cited

≥6 mmannular defect size referenced

PMAFDA PMA (Barricaid)

Coverage and Medical Necessity Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Not Medically Necessary / Unproven

The following procedures are considered unproven and not medically necessary due to insufficient evidence of efficacy:

Not Medically Necessary Procedures: Annular closure devices (ACDs); Percutaneous injection of allogeneic cellular/tissue-based products; Thermal intradiscal procedures (TIPs) for treating discogenic pain.

Listed as unproven / not medically necessary in Coverage Rationale.

inv-02: Annular Closure Devices (ACD) — coverage considerations

Evidence from randomized and nonrandomized studies shows potential benefit in select patients with large annular defects; coverage considerations depend on meeting specific selection criteria and informed consent regarding risks.

ACD coverage candidate criteria: Patient undergoing limited lumbar discectomy for symptomatic lumbar disc herniation AND intraoperative large annular defect (commonly ≥ 6 mm width) AND single-level disease (L4–S1) consistent with device labeling AND preserved disc height and acceptable bone quality (non-osteoporotic) AND documentation of prior conservative care failure (> 6 weeks) or indication for surgery (e.g., neurologic deficit) AND shared decision-making documented regarding device-specific risks (implantation difficulty, mesh migration/detachment, vertebral endplate changes)annular defect commonly ≥ 6 mm; device label: 4–6 mm tall and 6–10 mm wide

RCTs (Thomé et al., Kienzler et al., Nada et al.) demonstrated reduced reherniation and reoperation in selected patients but evidence quality varies; document defect measurements and single-level L4–S1 location per FDA PMA for Barricaid.

inv-03: Percutaneous intradiscal allogeneic cellular/tissue-based products — coverage stance

Insufficient high-quality evidence to support routine coverage; select use within clinical trials or research settings may be appropriate.

Allogeneic intradiscal injection coverage: Percutaneous intradiscal injection of allogeneic cellular/tissue-based products (e.g., viable nucleus pulposus allografts) is considered investigational/insufficient for routine coverage; coverage may be considered only with enrollment in a prospective clinical trial or when robust RCT-level justification and informed consent documenting experimental status are provided.

Hayes and ECRI reviews identified limited RCT evidence (Beall et al.) with inconsistent findings and small feasibility studies; further independent, adequately powered RCTs with long-term outcomes are required.

inv-04: Thermal intradiscal procedures (IDET, IDB, ID-PRF, PLN) — coverage stance

Evidence for thermal intradiscal procedures is mixed; some randomized trials and systematic reviews support select techniques (e.g., biacuplasty), while overall quality and consistency are limited.

IDB (biacuplasty): Intradiscal biacuplasty (IDB) has randomized trial evidence and systematic review support suggesting efficacy for chronic, refractory single-level discogenic pain compared to conventional medical management in selected patients; consider only when patient selection matches populations studied (single-level disease, prior conservative care, appropriate diagnostic testing).single-level discogenic pain; prior conservative care as in trials

Helm systematic review identified Level I evidence for biacuplasty based on RCTs, but larger/sham-controlled trials remain limited.

IDET: Intradiscal electrothermal therapy (IDET) evidence is mixed with moderate-level support from systematic review (Level III); outcomes are inconsistent across trials and routine coverage is not supported without case-specific justification.inconsistent trial results

One high-quality and one moderate-quality RCT reported differing results; consider restrictive coverage or case-by-case review.

inv-05: Procedure-specific coverage considerations — Coverage stance varies by procedure and device based on available evidence and FDA labeling.

Coverage stance varies by specific procedure and device based on available evidence quality and, where applicable, FDA labeling.

Procedures supported by RCT/systematic review evidence: Procedures such as intradiscal biacuplasty may have supportive RCT(s) and systematic review evidence for selected patients; coverage decisions should require documentation matching study populations (e.g., single-level disease, prior conservative care, diagnostic testing).match trial inclusion criteria

Helm systematic review and Desai RCTs provide evidence for IDB; require documentation of diagnostic testing and prior conservative care.

Procedures lacking sufficient evidence: Procedures without consistent RCT support (e.g., PIRFT/discTRODE, many intradiscal allograft injections) are considered investigational and not routinely covered except in clinical trials or with compelling justification.

Kvarstein RCT and Hayes/ECRI assessments identify insufficient evidence for routine use.

ACD (Barricaid) — device-specific guidance:

Percutaneous discectomy for axial or radicular pain is not covered under this policy. Providers should refer to the Medical Policy titled Minimally Invasive Spine Surgery Procedures for coverage and coding guidance when evaluating percutaneous discectomy requests.

Intradiscal injections of allogeneic cellular/tissue-based products and certain thermal intradiscal procedures are considered to have insufficient high-quality evidence to support routine use. The policy identifies the need for larger randomized controlled trials and longer-term outcomes to establish safety and efficacy for percutaneous allogeneic injections, and likewise notes limited-quality evidence for thermal intradiscal procedures.

Procedures that have not demonstrated benefit versus sham control—specifically intra-annular thermal therapies such as PIRFT with the discTRODE probe—are discouraged. A randomized, double-blind placebo trial of PIRFT found no significant advantage over sham and the authors advised against intra‑annular thermal therapy with the discTRODE probe; NICE guidance also characterizes evidence for percutaneous electrothermal treatments as inconsistent and of poor quality.

Summary: Annular closure devices (ACDs), percutaneous intradiscal allogeneic injections, and thermal intradiscal procedures are described in the policy as unproven or not medically necessary in many contexts due to limited, inconsistent, or low-quality evidence supporting clinical benefit.

Routine outpatient use of intradiscal allogeneic cellular/tissue-based products and unspecified thermal intradiscal procedures is not supported by the available evidence and therefore is not recommended outside of well‑designed clinical trials or highly selected research contexts.

A trial-level negative finding: PIRFT performed with the discTRODE probe did not demonstrate benefit over sham in a blinded RCT and the study authors stated they would not recommend intra‑annular thermal therapy using that device; this trial informed the policy conclusion regarding lack of demonstrated efficacy for PIRFT/discTRODE.

Applicable Codes and Coding Notes

Relevant CPT CodesCPT

0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level.
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level.
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level.
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine.
63032	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (List separately in addition to code for primary procedure).
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar.

ACD Procedure CodesCPT

63032	Laminotomy with repair of annular defect by implantation of bone-anchored annular closure device, including imaging guidance; 1 interspace, lumbar.
22899	Unlisted procedure, spine (may be used for ACD-related procedures not otherwise described).

Intradiscal Allograft Injection CodesCPTExperimental

0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, with fluoroscopic guidance; first lumbar level.
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, with fluoroscopic guidance; each additional lumbar level.
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, with CT guidance; first lumbar level.
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, with CT guidance; each additional lumbar level.

Thermal Intradiscal Procedure CodesCPT

22526	Percutaneous intradiscal electrothermal annuloplasty (IDET), single level, including fluoroscopic guidance.
22527	Percutaneous intradiscal electrothermal annuloplasty (IDET), additional levels.
S2348	Percutaneous decompression of nucleus pulposus using radiofrequency energy (may be reported for some nucleoplasty/biacuplasty procedures).
22899	Unlisted procedure, spine (for thermal intradiscal procedures not otherwise described).

Policy History — Code Updatesmixed

63032

Added to applicable CPT codes in 01/01/2026 policy update.

Annular Defect Size Threshold

Typical annular defect size considered in ACD studies≥ 6 mm

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Code-level Prior Authorization Reference

The following CPT/HCPCS codes are provided for prior authorization reference only. Verify plan-specific prior authorization processes and edits before submission.

Codes listed are for reference and do not guarantee coverage; follow member-specific benefit plan and UnitedHealthcare prior authorization workflows.
Confirm whether prior authorization is required for the procedure and specific code(s) noted; plan edits may change authorization requirements.

Denial Risk

ACD Selection Criteria Absent — Caution

Use ACDs (e.g., Barricaid) only for patients matching evidence-based candidate criteria; ACD use without a large annular defect lacks supporting evidence.

ACD selection should generally be limited to patients with a large annular defect (commonly ≥ 6 mm width) after single-level lumbar discectomy.
Avoid ACD implantation when a large annular defect is absent — evidence does not support benefit in these patients.

Documentation Required

Supporting Evidence and Documentation

Provide clinical evidence and documentation that aligns with the trials and systematic reviews summarized in this policy when requesting authorization; include conservative care history and relevant outcome measures when available.

Include supporting published evidence citations or summaries when available to justify medical necessity.
Document prior conservative care and objective measures referenced in the literature (e.g., ODI, VAS/NRS, imaging findings).
Note device-specific trial eligibility criteria where applicable (see ACD and Barricaid trial descriptions).

Documentation Required

ACD Preoperative Documentation

When requesting authorization for an annular closure device (ACD), document key preoperative findings that align with study inclusion criteria and device labeling.

Annular defect measurements (width and height) — document whether defect is large (commonly ≥ 6 mm width).
Confirm single-level lumbar involvement (L4–S1) and level(s) proposed for primary discectomy.
Preserved disc height at the treated level and bone mineral density status if clinically relevant.
Preoperative imaging (MRI) demonstrating neural compression and defect characteristics, and operative note from primary discectomy documenting annular defect size.

Prior Authorization

Intradiscal Allograft Documentation

For intradiscal allograft (percutaneous injection of allogeneic cellular/tissue-based products) prior authorization, supply detailed trial enrollment information or RCT-level justification, and document prior conservative therapy.

Specify the disc level(s) treated and number of levels planned.
Provide details of prior conservative care (duration and modalities) — most studies enrolled patients after failed conservative care (often ≥ 6 weeks to months).
If treatment is part of a trial, include trial name, enrollment criteria, and governance/IRB approval details; for non-trial use, provide RCT-level justification and rationale for an investigational approach.

Documentation Required

Annular Closure Device (Barricaid) Documentation

When considering the Barricaid annular closure device, document that candidate selection matches device-specific indications and trial-supported criteria.

Indicate the procedure is a primary single-level discectomy at L4–S1 with a large annular defect within the device labeling dimensions (between 4–6 mm tall and between 6–10 mm wide).
Describe rationale for device use (to reduce risk of reherniation/reoperation) and note known device risks (implantation difficulties, mesh detachment, migration, vertebral endplate changes).
Attach operative plan and anticipated implant details (bone-anchored ACD, imaging guidance) and reference FDA approval where applicable.

Documentation Required

Conservative Care Documented in Evidence

Document prior conservative care clearly; many studies required failure of conservative therapies (typically ≥ 6 weeks) before enrollment in trials of ACDs or intradiscal procedures.

Record duration and types of conservative therapies attempted (physical therapy, pharmacologic management, injections, activity modification, and other nonoperative measures).
Specify objective baseline measures (ODI, VAS/NRS) and response, and note contraindications to conservative care when applicable.
For intradiscal and thermal procedures, document that conventional medical management (CMM) was tried and failed as described in comparative trials.

Key Definitions

Annular Closure Device (ACD) — definition

DefinitionAnnular Closure Device (ACD): an implant designed to close or reinforce a defect in the annulus fibrosus after discectomy to prevent reherniation.

MechanismReinforces or bridges the annular defect to form a barrier between the annulus and nucleus pulposus.

Use casePlaced at time of limited lumbar discectomy to reduce recurrent lumbar disc herniation in select patients.

Thermal Intradiscal Procedures (TIPs) — definition

DefinitionThermal Intradiscal Procedures (TIPs): percutaneous procedures inserting a catheter or probe into the disc under imaging to apply heat aiming to denature collagen, shrink tissue, and disrupt nociceptors to relieve discogenic low back pain.

ExamplesIncludes IDET (intradiscal electrothermal therapy), IDB (intradiscal biacuplasty), and PIRFT (percutaneous intradiscal radiofrequency thermocoagulation).

Typical guidancePerformed under fluoroscopic (or CT) guidance as applicable.

Allogeneic cellular/tissue-based injections — definition

DefinitionAllogeneic cellular/tissue-based injections: donor-derived cell or tissue therapies injected percutaneously into the intervertebral disc to stimulate tissue repair.

Procedure routeInjected through the skin into lumbar discs (intradiscal injection).

Evidence stanceInsufficient high-quality evidence to support routine coverage; often limited to clinical trials or research contexts.

ACD implantable device example and typical use

Example deviceBarricaid (bone-anchored annular closure device) is an implantable ACD used to close large annular defects at the time of limited lumbar discectomy.

Typical timingImplanted intraoperatively at the time of primary limited lumbar discectomy for single-level disease (commonly L4–S1).

Intended effectAims to reduce recurrent herniation and reoperation in selected high-risk patients with large annular defects.

Allogeneic nucleus pulposus intradiscal injection — definition

Definition/exampleAllogeneic nucleus pulposus (NP) intradiscal injection: percutaneous injection of donor-derived viable nucleus pulposus tissue (e.g., Via Disc NP/VIADISC) into degenerative discs.

Intended goalAttempt structural or symptomatic improvement of degenerative disc disease by supplementing native NP tissue.

EvidenceEvidence includes feasibility studies and RCTs (e.g., VAST trial) but overall quality is insufficient for routine coverage.

IDB / IDET — definition (thermal intradiscal procedures)

DefinitionIntradiscal biacuplasty (IDB) / IDET: thermal intradiscal procedures that use radiofrequency energy or intradiscal electrothermal heating to denature collagen and modify annular nociceptors to relieve discogenic pain.

Technique distinctionIDET uses a flexible heating catheter placed at the annulus; IDB uses bilateral cooled radiofrequency electrodes to create controlled lesions.

PIRFT notePIRFT places an RF probe centrally in the disc for thermocoagulation (e.g., discTRODE technique).

Conventional Medical Management (CMM) — definition

DefinitionConventional Medical Management (CMM): combination of physical therapy, pharmacologic management, interventional procedures (lumbar epidural injections, sacroiliac joint injections, facet interventions), and lifestyle changes (behavioral therapy, weight loss, acupuncture).

Role in trialsCMM served as the comparator in RCTs of intradiscal procedures and is generally expected as prior conservative management before invasive procedures.

ComponentsIncludes PT, medications, interventional injections, and lifestyle/behavioral interventions.

Prerequisites: Conservative Therapy and Trial of Care

inv-43: Documentation of prior conservative care may be expected in supporting records (commonly > 6 weeks).

Documentation of prior conservative care may be expected in supporting records (commonly > 6 weeks).

Conservative care documentation expected: Medical records should document prior conservative management attempts (e.g., physical therapy, pharmacologic management, interventional injections, lifestyle measures) and duration, typically greater than 6 weeks, unless contraindicated.> 6 weeks

Studies and technology assessments generally included patients who had failed conservative care; documentation may be requested during prior authorization or review.

inv-44: Document failure of conservative therapy or contraindication prior to considering ACD or intradiscal procedures (commonly >6 weeks to several months).

Document failure of conservative therapy or contraindication prior to considering ACD (when not selected intraoperatively) or intradiscal procedures (commonly >6 weeks to several months).

Prior conservative therapy required before elective intradiscal or ACD consideration: Providers should document failure of appropriate conservative therapies (typically ≥ 6 weeks to several months) or document a contraindication to conservative management prior to elective consideration of intradiscal procedures or ACD implantation outside of intraoperative selection.commonly ≥ 6 weeks to several months

ACD trials and intradiscal procedure studies generally enrolled patients after failure of conservative care; for ACD, intraoperative identification of a large annular defect may be an exception to preoperative conservative therapy requirement.

inv-45: Conservative care (CMM) expected prior to intradiscal thermal procedures per trial comparators; specifics depend on member plan.

Conventional medical management (CMM) is expected as the comparator in trials and is generally expected prior to thermal intradiscal procedures; specifics depend on member plan.

CMM expected prior to thermal intradiscal procedures: Conventional medical management (CMM) — including physical therapy, pharmacologic management, appropriate interventional injections, and lifestyle modifications — is expected prior to intradiscal thermal procedures in many trial contexts and per typical plan expectations.

Randomized trials compared intradiscal procedures to CMM; document type and duration of CMM as applicable to prior authorization or medical record review.

Imaging and Diagnostic Testing Requirements

Billing Rule

Use and document imaging guidance (fluoroscopy or CT) for IDET/IDB/PIRFT and allogeneic injections

IDET/IDB/PIRFT and percutaneous allogeneic injections are performed under imaging guidance; ensure documentation indicates use of fluoroscopy or CT guidance as applicable.

IDET/IDB typically use fluoroscopic guidance during catheter/probe placement.
Allogeneic intradiscal injections may use fluoroscopy (0627T/0628T) or CT guidance (0629T/0630T); document modality used.

Documentation Required

Document provocative discography, MRI HIZ, and disc height when selecting for thermal procedures

Selection for thermal intradiscal procedures commonly relies on diagnostic testing such as provocative discography, MRI high-intensity zone (HIZ) findings, and assessment of disc height; include these diagnostic results in requests.

Provide discography results (e.g., DDS grade) and MRI findings (presence of HIZ) used to select patients.
Document disc height assessments and levels treated to align with study selection criteria.

Documentation Required

Provide MRI confirmation and imaging-based defect measurements for Barricaid candidacy

For Barricaid candidacy and other ACD considerations, provide MRI confirmation of neural compression and imaging-based annular defect measurements to support device selection.

Confirm imaging demonstrates neural compression and annular defect dimensions within the FDA-labeled range for Barricaid.
Include imaging that documents single-level L4–S1 involvement if relying on device labeling for coverage support.

OpenPayer

Discogenic Pain Treatment

Coverage and Medical Necessity Determinations

Applicable Codes and Coding Notes

Prior Authorization, Documentation, and Provider Requirements

Clinical Background

Key Definitions

Prerequisites: Conservative Therapy and Trial of Care

Procedure Frequency and Related Limits

Imaging and Diagnostic Testing Requirements

Not Covered Procedures